Transient leukemia in newborns without down syndrome: Diagnostic and management challenges

Journal of Pediatric Hematology/Oncology

Volumn 33, Issue 6, 2011, Pages

  Williams, Brent A ^a   Meyn, M Stephen ^a,b   Hitzler, Johann K ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

blasts; Down syndrome; neonatal; transient leukemia; transient myeloproliferative disorder; trisomy 21; trisomy 21 mosaicism

Indexed keywords

ANEMIA; ARTICLE; BRADYCARDIA; CASE REPORT; CHROMOSOME ANALYSIS; DOWN SYNDROME; ERYTHEMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC COUNSELING; HUMAN; HUMAN CELL; INFANT; LEUKEMIA; LEUKOCYTOSIS; MALE; MOSAICISM; NEWBORN; PRIORITY JOURNAL; SKIN BIOPSY; SKIN FIBROBLAST; THROMBOCYTOPENIA; TRANSIENT LEUKEMIA; TRISOMY 21;

CHROMOSOMES, HUMAN, PAIR 21; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT, NEWBORN; LEUKEMIA; MALE; MOSAICISM; PROGNOSIS; TRISOMY;

EID: 80051797660     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3182159f4e     Document Type: Article

References (17)

1. Zipursky A. Transient leukaemia: A benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol. 2003; 120:930-938. (Pubitemid 36411551)
2. Klusmann JH, Creutzig U, Zimmermann M, et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood. 2008;111:2991-2998.
3. Massey GV. Transient leukemia in newborns with Down syndrome. Pediatr Blood Cancer. 2005;44:29-32. (Pubitemid 39602562)
4. Zipursky A, Brown E, Christensen H, et al. Transient myeloproliferative disorder (Transient leukemia) and hematologic manifestations of Down Syndrome. Clin Lab Med. 1999; 19:157-167. (Pubitemid 29217322)
5. Li Z, Godinho FJ, Klusmann JH, et al. Developmental stageselective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. 2005;37:613-619. (Pubitemid 40770416)
6. Massey GV, Zipursky A, Chang MN, et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood. 2006;107:4606-4613. (Pubitemid 43882604)
7. Hitzler JK, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer. 2005;5:11-20. (Pubitemid 40052321)
8. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 2000;355:165-169. (Pubitemid 30068214)
9. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148-152. (Pubitemid 34977210)
10. Hitzler JK, Cheung J, Li Y, et al. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood. 2003;101:4301-4304. (Pubitemid 36857793)
11. Mundschau G, Gurbuxani S, Gamis AS, et al. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 2003;101:4298-4300. (Pubitemid 36857792)
12. Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003;102:981-986. (Pubitemid 36917793)
13. Al-Kasim F, Doyle JJ, Massey GV, et al. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study. J Pediatr Hematol Oncol. 2002;24:9-13. (Pubitemid 34094321)
14. Homans AC, Verissimo AM, Vlacha V. Transient abnormal myelopoiesis of infancy associated with trisomy 21. Am J Pediatr Hematol Oncol. 1993;15:392-399. (Pubitemid 23320137)
15. Isaacs H Jr. Fetal and neonatal leukemia. J Pediatr Hematol Oncol. 2003;25:348-361.
16. Papavassiliou P, York TP, Gursoy N, et al. The phenotype of persons having mosaicism for trisomy 21/Down syndrome reflects the percentage of trisomic cells present in different tissues. Am J Med Genet A. 2009;149A:573-583.
17. Committee on G. Health supervision for children with Down syndrome. Pediatrics. 2001;107:442-449.